CL2014000289A1 - Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica. - Google Patents
Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica.Info
- Publication number
- CL2014000289A1 CL2014000289A1 CL2014000289A CL2014000289A CL2014000289A1 CL 2014000289 A1 CL2014000289 A1 CL 2014000289A1 CL 2014000289 A CL2014000289 A CL 2014000289A CL 2014000289 A CL2014000289 A CL 2014000289A CL 2014000289 A1 CL2014000289 A1 CL 2014000289A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- compounds
- naphthyridones
- dihydro
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177119 | 2011-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000289A1 true CL2014000289A1 (es) | 2014-07-11 |
Family
ID=46650549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000289A CL2014000289A1 (es) | 2011-08-10 | 2014-02-05 | Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica. |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US8906923B2 (esLanguage) |
| EP (1) | EP2742045B1 (esLanguage) |
| JP (2) | JP5921687B2 (esLanguage) |
| KR (1) | KR101996862B1 (esLanguage) |
| CN (2) | CN103874698B (esLanguage) |
| AR (1) | AR087508A1 (esLanguage) |
| AU (1) | AU2012293621B2 (esLanguage) |
| BR (1) | BR112014003063B1 (esLanguage) |
| CA (1) | CA2842518C (esLanguage) |
| CL (1) | CL2014000289A1 (esLanguage) |
| DK (1) | DK2742045T3 (esLanguage) |
| EA (1) | EA201490438A1 (esLanguage) |
| ES (1) | ES2721658T3 (esLanguage) |
| HU (1) | HUE042978T2 (esLanguage) |
| IL (1) | IL230549A (esLanguage) |
| JO (1) | JO3611B1 (esLanguage) |
| MX (1) | MX348128B (esLanguage) |
| PE (1) | PE20141410A1 (esLanguage) |
| PH (1) | PH12014500317A1 (esLanguage) |
| TR (1) | TR201905537T4 (esLanguage) |
| TW (1) | TWI568731B (esLanguage) |
| UA (1) | UA111210C2 (esLanguage) |
| UY (1) | UY34253A (esLanguage) |
| WO (1) | WO2013021054A1 (esLanguage) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3611B1 (ar) | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
| AU2012293619B2 (en) | 2011-08-10 | 2017-05-04 | Janssen Sciences Ireland Uc | Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| WO2014023814A1 (en) * | 2012-08-10 | 2014-02-13 | Janssen R&D Ireland | New antibacterial compounds |
| US9540324B2 (en) | 2013-09-26 | 2017-01-10 | Luc Therapeutics, Inc. | Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B |
| JO3579B1 (ar) * | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| US11014927B2 (en) | 2017-03-20 | 2021-05-25 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
| WO2019177975A1 (en) | 2018-03-12 | 2019-09-19 | The Board Of Trustees Of The University Of Illinois | Antibiotics effective for gram-negative pathogens |
| JP7450610B2 (ja) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | ピルビン酸キナーゼｒの活性化 |
| MA53668B1 (fr) | 2018-09-19 | 2024-06-28 | Novo Nordisk Health Care Ag | Traitement de la drépanocytose avec un composé activant la pyruvate kinase r |
| BR112021009106A2 (pt) | 2018-11-12 | 2021-08-10 | Debiopharm International S.A. | compostos antibióticos, métodos de fabricação dos mesmos, composições farmacêuticas que os contêm e seus usos |
| MA57202B1 (fr) | 2019-09-19 | 2025-09-30 | Novo Nordisk Health Care Ag | Compositions d'activation de la pyruvate kinase r (pkr) |
| CA3212074A1 (en) * | 2021-03-17 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215123A (en) * | 1979-05-07 | 1980-07-29 | American Home Products Corporation | Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| EP1225895B1 (en) | 1999-10-08 | 2005-05-04 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| CO5251397A1 (es) | 1999-10-08 | 2003-02-28 | Smithkline Beecham Corp | Inhibidores de fab i |
| HK1049656A1 (zh) | 1999-10-08 | 2003-05-23 | Smithkline Beecham Corporation | Fab i抑制剂 |
| US7049310B2 (en) | 2001-04-06 | 2006-05-23 | Affinium Pharmaceuticals, Inc. | Fab I inhibitors |
| CA2568914C (en) * | 2004-06-04 | 2013-09-24 | Affinium Pharmaceuticals, Inc. | Therapeutic agents, and methods of making and using the same |
| US7732612B2 (en) | 2004-09-09 | 2010-06-08 | Janssen Pharmaceutica, N.V. | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
| US7973060B2 (en) | 2005-10-13 | 2011-07-05 | Crystalgenomics, Inc. | Fab I inhibitor and process for preparing same |
| EP2687533B1 (en) * | 2006-07-20 | 2017-07-19 | Debiopharm International SA | Acrylamide derivatives as FAB I inhibitors |
| WO2008098374A1 (en) * | 2007-02-16 | 2008-08-21 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab i inhibitors |
| NZ599444A (en) | 2009-11-18 | 2014-02-28 | Fab Pharma Sas | Novel heterocyclic acrylamides and their use as pharmaceuticals |
| JP2014524409A (ja) | 2011-07-29 | 2014-09-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | Ｈｉｖの治療のための組成物および方法 |
| US8766017B2 (en) | 2011-07-29 | 2014-07-01 | Eastman Chemical Company | Integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid |
| AU2012293619B2 (en) | 2011-08-10 | 2017-05-04 | Janssen Sciences Ireland Uc | Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| AU2012293618B2 (en) | 2011-08-10 | 2017-04-20 | Janssen Sciences Ireland Uc | Antibacterial homopiperidinyl substituted 3,4 dihydro 1H (1,8)naphthyridinones |
| JO3611B1 (ar) * | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
-
2012
- 2012-08-07 JO JOP/2012/0223A patent/JO3611B1/ar active
- 2012-08-10 MX MX2014001600A patent/MX348128B/es active IP Right Grant
- 2012-08-10 CN CN201280038643.4A patent/CN103874698B/zh active Active
- 2012-08-10 JP JP2014524410A patent/JP5921687B2/ja not_active Expired - Fee Related
- 2012-08-10 AR ARP120102929A patent/AR087508A1/es active IP Right Grant
- 2012-08-10 TW TW101128885A patent/TWI568731B/zh not_active IP Right Cessation
- 2012-08-10 PE PE2014000186A patent/PE20141410A1/es active IP Right Grant
- 2012-08-10 PH PH1/2014/500317A patent/PH12014500317A1/en unknown
- 2012-08-10 EP EP12746093.9A patent/EP2742045B1/en active Active
- 2012-08-10 HU HUE12746093A patent/HUE042978T2/hu unknown
- 2012-08-10 BR BR112014003063-4A patent/BR112014003063B1/pt active IP Right Grant
- 2012-08-10 AU AU2012293621A patent/AU2012293621B2/en active Active
- 2012-08-10 EA EA201490438A patent/EA201490438A1/ru unknown
- 2012-08-10 US US14/237,862 patent/US8906923B2/en active Active
- 2012-08-10 DK DK12746093.9T patent/DK2742045T3/en active
- 2012-08-10 UY UY0001034253A patent/UY34253A/es active IP Right Grant
- 2012-08-10 CA CA2842518A patent/CA2842518C/en active Active
- 2012-08-10 KR KR1020147005329A patent/KR101996862B1/ko active Active
- 2012-08-10 TR TR2019/05537T patent/TR201905537T4/tr unknown
- 2012-08-10 CN CN201511000870.XA patent/CN105461684B/zh active Active
- 2012-08-10 ES ES12746093T patent/ES2721658T3/es active Active
- 2012-08-10 WO PCT/EP2012/065733 patent/WO2013021054A1/en not_active Ceased
- 2012-10-08 UA UAA201400628A patent/UA111210C2/uk unknown
-
2014
- 2014-01-20 IL IL230549A patent/IL230549A/en active IP Right Grant
- 2014-02-05 CL CL2014000289A patent/CL2014000289A1/es unknown
- 2014-11-24 US US14/552,108 patent/US9290493B2/en active Active
-
2016
- 2016-03-16 US US15/071,612 patent/US9617262B2/en active Active
- 2016-04-12 JP JP2016079689A patent/JP2016190843A/ja not_active Withdrawn
-
2017
- 2017-03-09 US US15/454,703 patent/US9884864B2/en active Active
- 2017-12-18 US US15/845,854 patent/US10155759B2/en active Active
-
2018
- 2018-11-16 US US16/194,052 patent/US10501463B2/en active Active
-
2019
- 2019-02-26 US US16/286,383 patent/US10526331B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000289A1 (es) | Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica. | |
| CL2014000746A1 (es) | Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer. | |
| CL2013001282A1 (es) | Sal succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico; composicion farmaceutica que la comprende y procesos para su preparacion. | |
| CL2014003566A1 (es) | Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson. | |
| CL2013001713A1 (es) | Compuestos derivados de bemzimidazol, proceso para prepar dichos compuestos; composicion farmaceutica que los comprende; proceso para preparar esta composicion farmaceutica; y su uso para inhibir la replicacion del visus sincicial respiratorio (rsv). | |
| CU20130115A7 (es) | Compuestos y composiciones como inhibidores de trk | |
| CL2014000183A1 (es) | Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación. | |
| ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| BR112014003681A8 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
| UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
| BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
| UY34210A (es) | Composiciones, métodos y sistemas para la micropropagación de plantas | |
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| PH12015500260A1 (en) | Neprilysin inhibitors | |
| ES2603028T8 (es) | Procedimiento para la preparación de (Z)-alfa-fluoro-beta-amino-acrilaldehídos sustituidos | |
| BR112013020362A2 (pt) | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem | |
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| UY33917A (es) | ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?. | |
| BR112014030743A2 (pt) | inibidores de neprilisina | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| BR112014004310A2 (pt) | composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto | |
| BR112013032876A2 (pt) | uso de formulações, e, método para fertilizar plantas | |
| GT201400090A (es) | 2-tiopirimidinonas | |
| CL2014002986A1 (es) | Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k. | |
| EP2738153A4 (en) | PROCESS FOR PREPARING 3,3-DIMETHYL-BUTYRALDEHYDE |